Open AccessPotentiating aminoglycoside antibiotics to reduce their toxic side effects
Author(s) -
Christopher R. Rosenberg,
Xin Fang,
Kyle R Allison
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0237948
Subject(s) - aminoglycoside , antibiotics , bacteria , microbiology and biotechnology , metabolite , salmonella enterica , gentamicin , cytotoxicity , biology , escherichia coli , klebsiella pneumoniae , ototoxicity , chemistry , pharmacology , salmonella , biochemistry , cisplatin , chemotherapy , genetics , gene , in vitro
The lack of new antibiotics necessitates the improvement of existing ones, many of which are limited by toxic side effects. Aminoglycosides, antibiotics with excellent activity and low bacterial resistance, are hampered by dose-dependent toxic effects in patients (nephrotoxicity, ototoxicity). High antibiotic concentrations are often required to treat dormant, non-dividing bacteria, though previous studies show that aminoglycosides can be activated against such bacteria by specific metabolites. Here, we employed this mechanism to greatly boost the activity of low concentrations of aminoglycosides against prevalent Gram-negative pathogens ( Escherichia coli , Salmonella enterica , and Klebsiella pneumoniae ), suggesting that less toxic drug concentrations might be used effectively in patients. We go on to show that this effect improved treatment of biofilms, did not increase aminoglycoside resistance, and was due to the generation of proton-motive force (PMF). By single-cell microscopy, we demonstrate that stationary-phase cells, while non-dividing, actively maintain a growth-arrested state that is not reversed by metabolite addition. Surprisingly, within starved populations, we observed rare cells (3%) that divided without added nutrients. Additionally, we discovered that mannitol could directly protect human kidney cells from aminoglycoside cytotoxicity, independent of the metabolite’s effect on bacteria. This work forwards a mechanism-based strategy to improve existing antibiotics by mitigating their toxic side effects.